BioFIT is Europe’s leading partnering event in Life Sciences for tech transfer, early-stage innovation deals and pre-seed, seed and Series A investment, receiving each year more than 1,000 delegates from over 35 countries. For its 11th edition, BioFIT will be held in Strasbourg, France on November 29th and 30th, and on a digital format on December 7th and 8th.
Neotiv GmbH closes €10m seed financing
Latest NewsGerman Neotiv GmbH hat closed a €10m seed financing to speed-up product launch of its early diagnosis app for Alzheimer’s disease
Sourcing innovation in the Life Sciences sector
BackgroundBioFIT is Europe’s leading partnering event in Life Sciences for tech transfer, early-stage innovation deals and pre-seed, seed and Series A investment, receiving each year more than 1,000 delegates from over 35 countries. For its 11th edition, BioFIT will be held in Strasbourg, France on November 29th and 30th, and on a digital format on December 7th and 8th.
Jolt Capital boosts BC Platforms with $20m
Latest NewsJolt Capital contributed $20m to the BC Platforms’ data footprint expansion on November 8th.
Fungal skin replaces plastics in electronics
Latest NewsResearchers from the University of Linz (Austria) report progress on the way to make electronic devices more sustainable and more recyclable
Novadip Biosciences SA raises €40m
Latest NewsWth a Series B €40m financing, Novadip Biosciences SA has raised investements to a total of €88m. It will use the proceeds to push two single-use cell therapies designed to accelerate healing.
Benefits of booster campaigns questionable
Latest NewsThree small-scale studies hinted at new COVID-19 vaccination boosters not significantly enhancing the immune response to Omicron variant.
AMR joint venture Aurobac appoints CEO
AppointmentsAurobac Therapeutics has appointed Florence Séjourné as CEO. The French company is a joint venture, founded by Boehringer Ingelheim, Evotec and bioMérieux and focuses on combating antimicrobial resistance (AMR).
Pulsating biotech location
BackgroundTakeda, Boehringer Ingelheim and Novartis do it repeatedly. Global players make major investments in their Austrian facilities. Not only multinationals but start-ups and scale-ups such as Apeiron Biologics and ViraTherapeutics benefit from a comprehensive ecosystem – from basic research to production and distribution. The business location agency ABA is the first point of contact for setting up operations in Austria.
Tubes from cooking oil?
Sponsored PublicationsEppendorf Tubes® BioBased reduce the product-specific carbon footprint and support environmental friendly lab workflow.
Memo Therapeutics and Ono Pharmaceutical enter partnership
Latest NewsAntibody developer Memo Therapeutics AG has snaged a R&D partnership with Ono Pharmaceutical Co. Ltd in the immuno-oncology field.